Prostatic acid phosphatase (PAP)
Acid phosphatase (CF) catalyzes the hydrolysis of esters of phosphoric acid and organic compounds. This lysosomal enzyme is found in virtually all tissues. The highest concentration is observed in the epithelium of the prostate gland (prostatic fraction), then in the liver, spleen, erythrocytes (extraisosomal localization), thrombocytes, bone marrow. High activity of acid phosphatase is noted in macrophages and osteoclasts. The activity of acidic phosphatase of the prostate gland does not appear until the sexual maturity. In men, the total acidic serum phosphatase consists of prostatic CF and, in part, the CP of the liver and CF resulting from the destroyed platelets and erythrocytes. It is the main component of seminal fluid, it is detected in sperm, urine, in insignificant concentrations in the blood. There are no circadian fluctuations in the norm, however, in prostate cancer (PCa) there are diurnal fluctuations, which must be taken into account in the dynamic control of the level of the prostatic CF. The main clinical significance is monitoring the effectiveness of treatment with PCa (hormonal, surgical removal - reduced to undetectable levels after cardinal and effective removal). At the diagnostic stage, it has a low diagnostic sensitivity of 40%, but high specificity is 80%, so it can only be used as an additional marker. Does not correlate with the mass of the tumor. It is effective to use for the control of relapse and metastases (however it is effective only in 50% of patients). which must be taken into account in the dynamic control of the level of prostatic CF. The main clinical significance is monitoring the effectiveness of treatment with PCa (hormonal, surgical removal - reduced to undetectable levels after cardinal and effective removal). At the diagnostic stage, it has a low diagnostic sensitivity of 40%, but high specificity is 80%, so it can only be used as an additional marker. Does not correlate with the mass of the tumor. It is effective to use for the control of relapse and metastases (however it is effective only in 50% of patients). which must be taken into account in the dynamic control of the level of prostatic CF. The main clinical significance is monitoring the effectiveness of treatment with PCa (hormonal, surgical removal - reduced to undetectable levels after cardinal and effective removal). At the diagnostic stage, it has a low diagnostic sensitivity of 40%, but high specificity is 80%, so it can only be used as an additional marker. Does not correlate with the mass of the tumor. It is effective to use for the control of relapse and metastases (however it is effective only in 50% of patients). but high specificity - 80%, therefore can be used only as an additional marker. Does not correlate with the mass of the tumor. It is effective to use for the control of relapse and metastases (however it is effective only in 50% of patients). but high specificity - 80%, therefore can be used only as an additional marker. Does not correlate with the mass of the tumor. It is effective to use for the control of relapse and metastases (however it is effective only in 50% of patients).